Analyst Rating Update on Zimmer Biomet Holdings (ZBH)

Zimmer Biomet Holdings (NYSE:ZBH) : The consensus on Zimmer Biomet Holdings (NYSE:ZBH) based on 22 analyst recommendation on the company stock is 1.7, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 13 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Zimmer Biomet Holdings (NYSE:ZBH) stock is expected to deviate a maximum of $8.97 from the average target price of $128.57 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $135 and the most muted being $105.

For the current week, the company shares have a recommendation consensus of Buy. Also, Guggenheim Securities initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH). The current rating of the shares is Neutral, according to the research report released by the firm. The rating by the firm was issued on June 9, 2016.

Zimmer Biomet Holdings (NYSE:ZBH): stock turned positive on Tuesday. Though the stock opened at $116.62, the bulls momentum made the stock top out at $117.42 level for the day. The stock recorded a low of $115.52 and closed the trading day at $117.32, in the green by 1.72%. The total traded volume for the day was 1,379,301. The stock had closed at $115.34 in the previous days trading.

In an insider trading activity, Collins Tony W., officer (VP, Controller and CAO) of Zimmer Biomet Holdings, Inc., unloaded 3,611 shares at an average price of $116.43 on June 14, 2016. The total amount of the transaction was worth $420,429, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.